Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

T hree Months Ended September 30 , 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	2,047			$	—			$	—			$	2,047
License revenue			4,726				—				—				4,726
Grant and other revenue			106,729				154,887				—				261,616
Total revenue			113,502				154,887				—				268,389
Cost of revenue			82				—				—				82
Research and development expenses			1,251,383				126,615				—				1,377,998
Selling, general and administrative expenses, excluding depreciation and amortization (1)			—				—				1,773,532				1,773,532
Depreciation and amortization (2)			4,027				—				11,375				15,402
(Loss) income from operations (3)			(1,268,605	)			28,272				(1,784,907	)			(2,898,625	)
Other expense (4)			—				—				(713	)			(713	)
Net (loss) income			(1,141,990	)			28,272				(1,785,620	)			(2,899,338	)
Total assets, net of depreciation and amortization:
United States		$	1,000			$	38,320			$	5,839,733			$	5,879,053
International			116,782				—				—				116,782
Capital expenditures			120,810				—				—				120,810

T hree Months Ended September 30, 2019		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	4,895			$	—			$	—			$	4,895
Grant and other revenue			77,049				154,867				—				231,916
Total revenue			81,944				154,867				—				236,811
Cost of revenue			195				—				—				195
Research and development expenses			1,678,423				123,135				—				1,801,558
Selling, general and administrative expenses, excluding depreciation and amortization (1)			—				1,052				1,484,155				1,485,207
Depreciation and amortization (2)			—				—				34,289				34,289
(Loss) income from operations (3)			(1,596,674	)			30,680				(1,518,444	)			(3,084,438	)
Other income (4)			—				—				10,334				10,334
Income tax (expense) benefit			(72	)			16				55				—
Net (loss) income			(1,596,746	)			30,696				(1,508,055	)			(3,074,104	)
Total assets, net of depreciation and amortization:
United States		$	36,811			$	93,860			$	4,688,379			$	4,819,050
International			2,606				—				—				2,606

Nine Months Ended September 30, 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	26,188			$	—			$	—			$	26,188
License revenue			4,726				—				—				4,726
Grant and other revenue			381,103				283,745				—				664,848
Total revenue			412,017				283,745				—				695,762
Cost of revenue			1,048				—				—				1,048
Research and development expenses			3,402,160				256,886				—				3,659,046
Selling, general and administrative expenses, excluding depreciation and amortization (1)			—				(550	)			4,895,328				4,894,778
Depreciation and amortization (2)			4,027				—				47,474				51,501
(Loss) income from operations (3)			(2,995,218	)			27,409				(4,942,802	)			(7,910,611	)
Other income (4)			—				—				12,045				12,045
Net (loss) income			(2,995,218	)			27,409				(4,930,757	)			(7,898,566	)
Total assets, net of depreciation and amortization:
United States		$	1,000			$	38,320			$	5,839,733			$	5,879,053
International			116,782				—				—				116,782
Capital expenditures			120,810				—				8,406				129,216

Nine Months Ended September 30, 2019		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	13,985			$	—			$	—			$	13,985
License revenue			9,953				—				—				9,953
Grant and other revenue			309,670				204,919				—				514,589
Total revenue			333,608				204,919				—				538,527
Cost of revenue			6,559				—				—				6,559
Research and development expenses			3,194,468				418,315				—				3,612,783
Selling, general and administrative expenses, excluding depreciation and amortization (1)			—				15,828				4,985,990				5,001,818
Depreciation and amortization (2)			—				—				107,794				107,794
Loss from operations (3)			(2,867,419	)			(229,224	)			(5,093,784	)			(8,190,427	)
Other income (4)			—				—				17,456				17,456
Provision for income tax			(248	)			(20	)			(439	)			(707	)
Net loss from continuing operations			(2,867,667	)			(229,244	)			(5,076,767	)			(8,173,678	)
Loss from discontinued operations, net of tax			(2,665	)			—				—				(2,665	)
Net loss			(2,870,332	)			(229,244	)			(5,076,767	)			(8,176,343	)
Total assets, net of depreciation and amortization:
United States		$	36,811			$	93,860			$	4,688,379			$	4,819,050
International			2,606				—				—				2,606